First-in-human dose-escalation study of ATR inhibitor BAY 1895344

• Research type

  Research Study

• Full title

  An open-label, first-in-human, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose and / or recommended Phase II dose of the ATR inhibitor BAY 1895344 in patients with advanced solid tumors and lymphomas

• IRAS ID

  218516

• Contact name

  Richard Sharp

• Contact email

  richard.sharp@bayer.com

• Sponsor organisation

  Bayer AG

• Eudract number

  2016-004484-39

• Duration of Study in the UK

  2 years, 3 months, 27 days

• Research summary

  The ATR inhibitor BAY 1895344 is developed for the treatment of patients with advanced solid tumours and lymphomas. The purpose of the proposed clinical trial is to evaluate the safety and tolerability of BAY 1895344, and to identify the maximum tolerated dose of BAY 1895344 that could be safely given to cancer patients. Further, the response of the cancer to the treatment will be determined.

• REC name

  London - Chelsea Research Ethics Committee

• REC reference

  17/LO/0591

• Date of REC Opinion

  26 May 2017

• REC opinion

  Further Information Favourable Opinion